With an oversubscribed trading debut now in the books, Veradermics—developing an oral version of the molecule behind ...

Veradermics, a developer of an oral treatment for pattern hair loss, began trading on the New York Stock Exchange with shares ...

The first of three pivotal clinical trials is expected to yield preliminary data in the first half of 2026.

Veradermics is set to raise $200 million in an IPO to fund its novel extended-release oral minoxidil for pattern hair loss.

An Initial Public Offering (IPO) is when a private company offers its shares to the public for the first time, allowing investors to buy a stake and the company to raise capital for growth.